Treatments

Many people still need support despite lifting of COVID-19 precautions--survey

Tue, 2022-10-25 11:18 — mike kraft

First on CNN: Most people feel socially connected as Covid-19 precautions ease, but many still need support, survey finds | CNN

...

Lots of research has been done on links between loneliness, social connection, health and well-being, but a new international survey by the analytics firm Gallup and Facebook’s parent company, Meta, aims to shed some light on exactly how connected people feel and how they connect with others.

They found that most people around the world feel a sense of social connection as Covid-19 precautions ease, but many still need support or help from others – and the factors that drive feelings of connection vary by country.

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Situation Report

Read more about Many people still need support despite lifting of COVID-19 precautions--survey
Log in or register to post comments

White House steps efforts to boost new bivalent COVID-19 shots

Tue, 2022-10-25 10:01 — mike kraft

Biden administration amps up efforts to boost new COVID-19 shots | The Hill

President Biden on Tuesday will announce a series of new efforts to boost the administration of the bivalent COVID-19 booster shots, including partnerships with several major companies and pharmacy chains.

...

Medicare will also be sending out email reminders to about 16 million people in the next week informing them of how they can get the updated booster.

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Read more about White House steps efforts to boost new bivalent COVID-19 shots
Log in or register to post comments

Ivermectin still nopt a good COVID-19 Treatment--large new trial

Mon, 2022-10-24 13:01 — mike kraft

Ivermectin: Still on a Losing Streak as COVID-19 Treatment | MedPage Today

WASHINGTON -- There were no differences in relief from mild-to-moderate COVID-19 symptoms for patients on ivermectin versus placebo, according to the ongoing ACTIV-6 trial.

Among >1,000 vaccinated and unvaccinated patients, the median time to recovery was 12 days for those in the ivermectin group and 13 days in the placebo group, reported Matthew McCarthy, MD, of Weill Cornell Medicine in New York City, at IDWeek.

As a result, the hazard ratio for improvement in time to recovery was 1.07 (95% credible interval 0.96-1.17, posterior P=0.91), McCarthy and colleagues stated in JAMA, where the results were simultaneously published.

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Read more about Ivermectin still nopt a good COVID-19 Treatment--large new trial
Log in or register to post comments

Omicron subvariants pose a new threat to people with immune deficiencies

Mon, 2022-10-24 09:53 — mike kraft

Omicron subvariants pose a new threat to people with immune deficiencies (nbcnews.com)

New versions of the omicron virus show resistance to the antibody drugs many need for extra protection against Covid.

---

People with compromised immune systems face a new winter of discontent as the ever-mutating omicron virus threatens to outrun the preventive monoclonal antibody cocktail that hundreds of thousands of them have relied upon for extra protection against Covid.

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Situation Report

Read more about Omicron subvariants pose a new threat to people with immune deficiencies
Log in or register to post comments

Analysis: Falling demand for COVID boosters makes price hikes more likely

Fri, 2022-10-21 17:06 — mike kraft

Analysis: Falling demand for COVID boosters puts price hikes on the table With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu vaccinations. Michael Erman Reuters

...

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Read more about Analysis: Falling demand for COVID boosters makes price hikes more likely
Log in or register to post comments

After the USG stops buying the shots, Pfizer says COVID-19 vaccine will cost $110-$130 per dose

Fri, 2022-10-21 13:15 — mike kraft

Pfizer says COVID-19 vaccine will cost $110-$130 per dose Pfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free. AP NEWS

...

Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots.

Country / Region Tags:

General Topic Tags: